查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593037

静脉铁剂市场：按产品和应用分类 - 全球预测 2025-2030

Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Dextran, Iron Sucrose), Application (Cancer, Chronic Kidney Disease, Inflammatory Bowel Disease) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年静脉注射铁剂市值为28.9亿美元，预计2024年将达到31.6亿美元，复合年增长率为9.65%，预计到2030年将达到55亿美元。

静脉铁剂市场的范围包括经由静脉途径给药的铁盐的开发和应用，以治疗缺铁和贫血，特别是当口服给药失败或不可行时。由于慢性肾臟病、癌症和其他导致贫血的疾病的盛行率不断增加，因此需要有效管理患者的铁水平，从而推动了该市场的发展。静脉补铁对于解决需要快速补充铁质的严重缺铁患者的贫血至关重要，例如在手术、癌症治疗和透析环境中，以及在医院、诊所和治疗中心，我们正在扩大静脉补铁的应用。关键的成长要素包括提高安全性和有效性的配方的进步、医院方案的更多采用以及更容易患贫血的老年人口的增加。利用伙伴关係关係扩大产品系列、改善销售管道并增加新兴市场的可近性存在潜在机会。建议重点研发，开发副作用最小的新剂型，能获得病人接受，扩大市场。然而，其使用也存在一些限制，包括严格的法律规范、高成本以及过敏反应等潜在副作用。此外，竞争对手的专利保护策略也为新参与企业带来了市场进入挑战。创新将致力于创造更安全、更有效的输送机制，并开拓贫血以外的新治疗适应症。该市场竞争激烈，其特点是製药公司和医疗保健提供者之间不断合作，以改善患者的治疗结果。为了取得成功，公司必须预测监管变化，在药物开发中优先考虑患者安全，并利用生物技术的进步来保持竞争优势。与医疗保健专业人士合作，以获取有关静脉补铁剂的益处和风险的真实世界证据和透明沟通，对于增强市场信心和成长至关重要。

主要市场统计
基准年[2023] 28.9亿美元
预测年份 [2024] 31.6亿美元
预测年份 [2030] 55亿美元
复合年增长率（%） 9.65%

市场动态：快速发展的静脉铁剂市场的关键市场洞察

供需的动态交互作用正在改变静脉铁剂市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性肾臟病盛行率不断上升
    • 需要预防孕妇贫血并改善孕产妇和分娩结果
    • 医疗保健领域投资，医疗费用增加
  • 市场限制因素
    • 医药品认证过程严格规定
  • 市场机会
    • 加大开发新药研究力度
    • 改善供应链和分销网络
  • 市场挑战
    • 与静脉铁剂相关的副作用

波特五力：驾驭静脉铁剂市场的策略工具

波特的五力框架是了解静脉铁剂市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对静脉铁剂市场的影响

外部宏观环境因素对静脉铁剂市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解静脉铁剂市场的竞争状况

对静脉铁剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位静脉注射基质铁市场供应商绩效评估

FPNV定位矩阵是评估静脉铁剂市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘静脉铁剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，静脉铁剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性肾臟病盛行率增加
      • 需要预防孕妇贫血并改善孕产妇和分娩结果
      • 医疗保健领域投资，药品支出增加
    • 抑制因素
      • 严格药品核准流程规定
    • 机会
      • 加大开发新药研究力度
      • 改善供应链和分销网络
    • 任务
      • 与静脉铁剂相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章静脉铁剂市场：副产品

  • Ferric carboxymaltose
  • 聚葡萄糖铁
  • 蔗糖铁

第七章 静脉铁剂市场：依应用分类

  • 癌症
  • 慢性肾臟病
  • 发炎性肠道疾病

第八章 北美、南美静脉铁剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太静脉铁剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东、非洲静脉注射铁剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories Inc
  • Actavis, Inc.
  • Allergan, Inc.
  • AMAG Pharmaceuticals. Inc.
  • American Regent. Inc.
  • Baxter International Inc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Ltd.
  • Fresenius Medical Care AG & Co.
  • Galenica Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.
  • Sanofi AG
  • Shield Therapeutics PLC
  • Vifor Pharma Management Ltd.
Product Code: MRR-22146147736D

The Intravenous Iron Drugs Market was valued at USD 2.89 billion in 2023, expected to reach USD 3.16 billion in 2024, and is projected to grow at a CAGR of 9.65%, to USD 5.50 billion by 2030.

The scope of the intravenous iron drugs market encompasses the development and application of iron salts administered via intravenous routes to treat iron deficiency and anemia, particularly when oral administration fails or isn't feasible. This market is primarily driven by the growing prevalence of chronic kidney disease, cancer, and other conditions leading to anemia, necessitating efficient management of iron levels in patients. Intravenous iron drugs are essential in addressing anemia in those with severe iron-deficiency where rapid replenishment of iron is required, such as in surgical, cancer treatment, or dialysis settings, broadening its application across hospitals, clinics, and treatment centers. Key growth influencers include advancements in drug formulations enhancing safety and efficacy, increasing adoption in hospital protocols, and a rising geriatric population more prone to anemia. Potential opportunities lie in expanding product portfolios, improving distribution channels, and leveraging partnerships to enhance accessibility in emerging markets. A recommendation is to focus on R&D to develop new formulations that minimize side effects, thus broadening patient acceptance and market reach. However, limitations include stringent regulatory frameworks, high costs, and potential side effects like allergic reactions, which can limit usage. Additionally, competitors' patent protection strategies pose challenges to market entry for new players. Innovation can be directed towards creating safer, more efficient delivery mechanisms and exploring new therapeutic indications beyond anemia. The market is competitive, characterized by continuous collaboration between pharmaceutical companies and healthcare providers to improve patient outcomes. To succeed, companies must anticipate regulatory changes, prioritize patient safety in drug development, and harness advances in biotechnology to maintain competitive advantage. Collaboration with healthcare professionals for real-world evidence and transparent communication about benefits and risks of intravenous iron drugs are essential for fostering market confidence and growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.89 billion
Estimated Year [2024] USD 3.16 billion
Forecast Year [2030] USD 5.50 billion
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intravenous Iron Drugs Market

The Intravenous Iron Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic kidney disease
    • Need for preventing anemia in pregnant women as well as improving maternal and birth outcomes
    • Investment in the healthcare sector, higher spending on medicine
  • Market Restraints
    • Stringent regulations with the drug approval process
  • Market Opportunities
    • Increasing research in new drug development
    • Improvements in supply chain and distribution network
  • Market Challenges
    • Side-effects related to Intravenous Iron drugs

Porter's Five Forces: A Strategic Tool for Navigating the Intravenous Iron Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intravenous Iron Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intravenous Iron Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intravenous Iron Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intravenous Iron Drugs Market

A detailed market share analysis in the Intravenous Iron Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intravenous Iron Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intravenous Iron Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intravenous Iron Drugs Market

A strategic analysis of the Intravenous Iron Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Iron Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc, Actavis, Inc., Allergan, Inc., AMAG Pharmaceuticals. Inc., American Regent. Inc., Baxter International Inc, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Fresenius Medical Care AG & Co., Galenica Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pharmacosmos A/S, Rockwell Medical, Inc., Sanofi AG, Shield Therapeutics PLC, and Vifor Pharma Management Ltd..

Market Segmentation & Coverage

This research report categorizes the Intravenous Iron Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Ferric Carboxymaltose, Iron Dextran, and Iron Sucrose.
  • Based on Application, market is studied across Cancer, Chronic Kidney Disease, and Inflammatory Bowel Disease.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic kidney disease
      • 5.1.1.2. Need for preventing anemia in pregnant women as well as improving maternal and birth outcomes
      • 5.1.1.3. Investment in the healthcare sector, higher spending on medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations with the drug approval process
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research in new drug development
      • 5.1.3.2. Improvements in supply chain and distribution network
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects related to Intravenous Iron drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intravenous Iron Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Ferric Carboxymaltose
  • 6.3. Iron Dextran
  • 6.4. Iron Sucrose

7. Intravenous Iron Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Chronic Kidney Disease
  • 7.4. Inflammatory Bowel Disease

8. Americas Intravenous Iron Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Intravenous Iron Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Intravenous Iron Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc
  • 2. Actavis, Inc.
  • 3. Allergan, Inc.
  • 4. AMAG Pharmaceuticals. Inc.
  • 5. American Regent. Inc.
  • 6. Baxter International Inc
  • 7. Bayer AG
  • 8. Bristol-Myers Squibb Company
  • 9. Daiichi Sankyo Company, Ltd.
  • 10. Fresenius Medical Care AG & Co.
  • 11. Galenica Ltd.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Pharmacosmos A/S
  • 16. Rockwell Medical, Inc.
  • 17. Sanofi AG
  • 18. Shield Therapeutics PLC
  • 19. Vifor Pharma Management Ltd.

LIST OF FIGURES

  • FIGURE 1. INTRAVENOUS IRON DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INTRAVENOUS IRON DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INTRAVENOUS IRON DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INTRAVENOUS IRON DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRAVENOUS IRON DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRAVENOUS IRON DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY FERRIC CARBOXYMALTOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON DEXTRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY IRON SUCROSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IRON DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INTRAVENOUS IRON DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. INTRAVENOUS IRON DRUGS MARKET, FPNV POSITIONING MATRIX, 2023